68

Beijing Balance Medical Technology Co Ltd

688198 · SHG · Healthcare / Medical Devices

68.07CNY-0.85 (-1.23%)

Price History

Full chart

Market Stats

Previous Close68.92
Open68.88
Day Range67.81 – 69.70
52-Week Range67.03 – 132.94
Volume274.24K
Market Cap9.45B
P/E (TTM)56.68
Forward P/E0.00
EPS1.21
Dividend Yield1.17%
Beta-0.03
50-Day Avg75.87
200-Day Avg92.18

About

Beijing Balance Medical Technology Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of artificial bioprosthetic valve medical devices in China and internationally. It offers bovine pericardial, porcine aortic tissue, and limiting expandable artificial biological heart valves, as well as tricuspid annuloplasty ring for heart valve repair and treatment. The company also provides outflow tract single valve patch, pulmonary valved conduit, cardiothoracic biopatch, thoracic surgery biological patch, and dacron patch, as well as ventricular septal defect occluder, PDA occluder, ASD occluder, and cardiovascular occluder delivery system for congenital heart disease treatment. In addition, it offers neurosurgery microvascular pressure relief gasket, neurosurgical biopatch, and biological hernia patch for soft tissue repair. The company was founded in 2001 and is headquartered in Beijing, China.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEODr. Lei Jin
  • Employees841
  • HeadquartersNo. 2 Huachang Road, Beijing, China, 102200, China
  • Websitehttps://www.balancemed.cn

Leadership

  • Dr. Lei JinChairman of the Board & GM · b. 1954
  • Ms. Qi ChengFinancial Director & Director · b. 1968
  • Ms. Liyan LiDeputy GM & Director · b. 1980
  • Mr. Wuping LiDeputy GM & Director · b. 1978
  • Tao ZhangAccounting Supervisor
  • Ms. Xiaozhou GuanBoard Secretary · b. 1984

Financials

Income Statement

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue78.46M92.35M110.65M146.03M181.92M251.82M295.17M370.64M501.88M620.15M
Growth (%)-+17.70%+19.82%+31.98%+24.57%+38.42%+17.21%+25.57%+35.41%+23.57%
Cost of Revenue9.35M10.05M9.91M13.08M20.21M29.61M31.36M37.64M58.52M67.09M
Gross Profit69.11M82.30M100.74M132.95M161.71M222.21M263.81M333.00M443.35M553.06M
Gross Margin88.09%89.12%91.05%91.04%88.89%88.24%89.38%89.84%88.34%89.18%
Operating Expense31.91M39.38M61.49M65.00M112.91M186.09M177.96M228.70M305.24M347.26M
Operating Income37.20M42.93M39.26M67.95M48.80M36.12M85.85M104.30M138.12M205.80M
Operating Margin47.42%46.48%35.48%46.53%26.83%14.34%29.09%28.14%27.52%33.19%
EBITDA-54.13M46.81M78.41M54.47M56.81M113.04M134.13M174.41M249.73M
EBITDA Margin-58.62%42.31%53.69%29.94%22.56%38.30%36.19%34.75%40.27%
Net Income31.17M42.20M33.40M63.08M56.53M51.20M95.14M115.21M146.33M193.57M
Net Income Margin39.73%45.70%30.19%43.20%31.07%20.33%32.23%31.08%29.16%31.21%
R&D11.43M11.78M12.89M15.15M28.77M58.90M55.15M98.81M151.44M155.33M
R&D as % of Total Revenue14.57%12.75%11.65%10.37%15.81%23.39%18.68%26.66%30.17%25.05%
Interest Expense00448.36K349.70K1.05M118.61K79.89K414.74K462.63K1.44M
Interest Expense % of Total Revenue0.00%0.00%0.41%0.24%0.58%0.05%0.03%0.11%0.09%0.23%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets123.52M146.63M210.05M788.29M871.44M1.03B1.18B1.33B1.43B1.62B
Total Liabilities29.67M12.98M14.01M23.39M35.62M42.73M80.17M138.47M180.28M309.83M
Total Equity93.96M133.96M196.61M765.68M837.20M989.51M1.10B1.19B1.25B1.33B
Cash47.59M79.36M145.63M718.49M149.57M156.78M128.30M295.31M56.01M39.72M
Net Debt---------35.28M

Cash Flow

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow45.07M46.38M53.92M63.88M50.76M76.49M128.85M141.17M136.23M197.79M
Investing Cash Flow----531.57K-596.94M-64.64M-115.02M---
Financing Cash Flow---509.51M-22.74M-9.29M-38.31M---
Capital Expenditure13.54M13.10M2.18M2.02M7.69M72.22M104.83M128.63M163.26M136.20M
Free Cash Flow-33.29M51.73M61.86M43.07M4.27M24.01M12.53M-27.02M61.60M
Dividends Paid14.62M-25.00M19.20M19.20M19.20M48.22M67.84M109.26M110.84M
FCF to OCF-71.76%95.95%96.84%84.84%5.58%18.64%8.88%-19.84%31.14%
Dividend Paid to FCF--48.32%31.04%44.58%449.55%200.80%541.22%-404.32%179.94%

Earnings

Report DateNov 19, 2019Dec 31, 2019Apr 23, 2020Aug 19, 2020Oct 22, 2020Jan 29, 2021Apr 21, 2021Aug 15, 2021Oct 27, 2021Feb 21, 2022Apr 21, 2022Aug 28, 2022Oct 25, 2022Dec 31, 2022Apr 19, 2023
EPS Estimate0.00--------------
EPS Actual0.220.110.220.180.170.000.090.130.100.080.100.170.170.260.26
Surprise---------------
Timing--Pre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketAfter-hours-Pre-market

Key Statistics & Ratios

Market Cap9.45B
Enterprise Value10.08B
Trailing P/E56.68
Forward P/E0.00
Price / Sales15.09
Price / Book8.07
EPS1.21
Book Value9.10
Revenue (TTM)625.98M
Gross Profit (TTM)558.65M
EBITDA188.16M
Profit Margin26.53%
Operating Margin-10.46%
Return on Equity12.78%
Return on Assets6.37%
Shares Outstanding137.75M
Shares Float36.42M
Beta-0.03
Dividend Yield1.17%
Dividend Rate0.80
Payout Ratio66.12%

Dividends

20231×
0.50May 25, 2023
20221×
0.50May 26, 2022
20211×
0.14May 27, 2021
20201×
0.14Jul 3, 2020

Stock Splits

  • May 26, 20227:5